Form 8-K   

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION  

WASHINGTON, D.C. 20549  

FORM 8-K  

CURRENT REPORT  

PURSUANT TO SECTION 13 OR 15(d)  

OF THE SECURITIES EXCHANGE ACT OF 1934  

Date of Report (Date of earliest event reported): February 9, 2018 (February 8, 2018)  

ALLERGAN PLC  

(Exact Name of Registrant as Specified in Charter)  

  [DATA_TABLE_REMOVED] 

Clonshaugh Business and Technology Park  

Coolock, Dublin, D17 E400, Ireland  

(Address of Principal Executive Offices)  

(862) 261-7000  

(Registrant’s telephone number, including area code)  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):  

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

 Item 8.01 Other Events.  

On February 8, 2018, the Board of Directors (the “Board”) of Allergan plc (the “Company”) set a record date of March 6, 2018 for participation in the Company’s 2018 Annual General Meeting of Shareholders (the “2018 AGM”). Only those shareholders of the Company who are shareholders of record at the close of business on March 6, 2018 will be entitled to receive notice of, and to vote, at the 2018 AGM. The Board also set the date of the Company’s 2018 AGM as May 2, 2018.  

SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  

  [DATA_TABLE_REMOVED]